CY1119967T1 - Αναστολη πρωτεασης - Google Patents

Αναστολη πρωτεασης

Info

Publication number
CY1119967T1
CY1119967T1 CY20181100165T CY181100165T CY1119967T1 CY 1119967 T1 CY1119967 T1 CY 1119967T1 CY 20181100165 T CY20181100165 T CY 20181100165T CY 181100165 T CY181100165 T CY 181100165T CY 1119967 T1 CY1119967 T1 CY 1119967T1
Authority
CY
Cyprus
Prior art keywords
protest
suspension
proteins
genetically engineered
disclosed
Prior art date
Application number
CY20181100165T
Other languages
Greek (el)
English (en)
Inventor
Robert C. Ladner
Original Assignee
Dyax Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyax Corp. filed Critical Dyax Corp.
Publication of CY1119967T1 publication Critical patent/CY1119967T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/8107Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114Kunitz type inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CY20181100165T 2005-12-29 2018-02-09 Αναστολη πρωτεασης CY1119967T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75490305P 2005-12-29 2005-12-29
PCT/US2006/049322 WO2007079096A2 (en) 2005-12-29 2006-12-27 Protease inhibition

Publications (1)

Publication Number Publication Date
CY1119967T1 true CY1119967T1 (el) 2018-12-12

Family

ID=38228815

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100165T CY1119967T1 (el) 2005-12-29 2018-02-09 Αναστολη πρωτεασης

Country Status (14)

Country Link
US (1) US8828703B2 (enExample)
EP (1) EP1981519B1 (enExample)
JP (2) JP5632126B2 (enExample)
AU (1) AU2006332774A1 (enExample)
CA (1) CA2635589C (enExample)
CY (1) CY1119967T1 (enExample)
DK (1) DK1981519T3 (enExample)
ES (1) ES2663497T3 (enExample)
HU (1) HUE038243T2 (enExample)
LT (1) LT1981519T (enExample)
PL (1) PL1981519T3 (enExample)
PT (1) PT1981519T (enExample)
SI (1) SI1981519T1 (enExample)
WO (1) WO2007079096A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US20050222023A1 (en) * 2002-02-07 2005-10-06 Hans-Peter Hauser Albumin-fused kunitz domain peptides
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
ATE477020T1 (de) 2002-06-07 2010-08-15 Dyax Corp Prevention und verringerung von ischemia
EP2386310B1 (en) 2002-08-28 2018-11-07 Dyax Corp. Methods for preserving organs and tissues
AU2004268145B2 (en) * 2003-08-29 2010-09-16 Takeda Pharmaceutical Company Limited Poly-PEGylated protease inhibitors
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
JP5362349B2 (ja) 2005-04-15 2013-12-11 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト タンパク質を精製する方法
ES2531372T3 (es) * 2006-10-13 2015-03-13 Novo Nordisk Healthcare Ag Enzimas de procesamiento fusionadas a marcadores de proteínas básicas
CA2696208A1 (en) * 2007-08-21 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
WO2009026539A1 (en) * 2007-08-23 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
US20110262396A1 (en) * 2008-10-22 2011-10-27 Dyax Corp. Combination treatments comprising protease binding proteins for inflammatory disorders
CA2744235A1 (en) 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
AU2010222537B2 (en) * 2009-03-10 2016-06-30 Med Discovery Sa Use of serine protease inhibitors in the treatment of neutropenia
GB0916578D0 (en) * 2009-09-22 2009-10-28 Malmsten Nils M Polypeptides and uses thereof
PL2521568T3 (pl) 2010-01-06 2019-03-29 Dyax Corp. Białka wiążące kalikreinę osocza
US9597379B1 (en) * 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
KR102502293B1 (ko) 2011-01-06 2023-02-21 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
US10314909B2 (en) 2011-10-21 2019-06-11 Dyax Corp. Combination therapy comprising an MMP-14 binding protein
CA2897018C (en) 2013-01-07 2021-07-27 Omniox, Inc. Polymeric forms of h-nox proteins
HUE041332T2 (hu) 2013-01-20 2019-05-28 Dyax Corp Bradikinin-közvetített rendellenességek értékelése és kezelése
PT3060908T (pt) 2013-10-21 2021-05-27 Dyax Corp Diagnóstico e tratamento de doenças autoimunes
KR20250066486A (ko) 2013-10-21 2025-05-13 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 시스템 바이오마커를 결정하기 위한 검정법
PT3110434T (pt) 2014-02-24 2018-12-19 Takeda Pharmaceuticals Co Proteínas da fusão de uti
KR20230109785A (ko) 2014-03-27 2023-07-20 다케다 파머수티컬 컴패니 리미티드 당뇨병성 황반 부종의 치료를 위한 조성물 및 방법
JP7049832B2 (ja) 2015-03-17 2022-04-07 オムニオクス, インコーポレイテッド タンパク質媒介性o2送達による腫瘍免疫のモジュレーション
DK3365685T3 (da) 2015-10-19 2021-03-01 Dyax Corp Immunoassay til påvisning af spaltet højmolekylært kininogen
WO2017100679A1 (en) 2015-12-11 2017-06-15 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
JP6467073B2 (ja) * 2018-01-04 2019-02-06 オムニオクス, インコーポレイテッド H−noxタンパク質の重合体形態
KR20200143376A (ko) 2018-03-13 2020-12-23 샤이어 휴먼 지네틱 테라피즈 인크. 혈장 칼리크레인 억제제로서의 치환된 이미다조피리딘 및 이의 용도
JP2022544393A (ja) * 2019-08-12 2022-10-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッド マクロファージ刺激1受容体(mst1r)バリアント及びその使用
CN114667289B (zh) 2019-09-18 2025-08-26 武田药品工业有限公司 杂芳基血浆激肽释放酶抑制剂
US11787796B2 (en) 2019-09-18 2023-10-17 Takeda Pharmaceutical Company Limited Plasma Kallikrein inhibitors and uses thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0332640A1 (en) 1986-11-17 1989-09-20 California Biotechnology, Inc. Recombinant alzheimer's amyloid protein
US5106833A (en) 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
US4966852A (en) 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
IL87172A (en) 1987-07-23 1994-12-29 Univ Washington Method of isolating highly purified tissue factor inhibitor
IL87171A (en) 1987-11-23 1995-08-31 Monsanto Co cDNA of human tissue factor inhibitor
US5663143A (en) 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
US7078383B2 (en) 1988-09-02 2006-07-18 Dyax Corp. ITI-D1 Kunitz domain mutants as HNE inhibitors
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DK408089D0 (da) 1989-08-18 1989-08-18 Novo Nordisk As Proteiner
US5378614A (en) 1989-08-18 1995-01-03 Novo Nordisk A/S Vector and method for making tissue factor pathway inhibitor (TFPI) analogues in yeast
IL104327A0 (en) 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
IL104314A0 (en) 1992-01-07 1993-05-13 Novo Nordisk As Human kunitz-type protease inhibitor and variants thereof,their production and pharmaceutical compositions containing them
US5212091A (en) 1992-03-02 1993-05-18 Monsanto Company Method of producing tissue factor pathway inhibitor
US6063764A (en) 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
US5455338A (en) 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
EP0739355B1 (en) 1994-01-11 2004-09-08 Dyax Corporation Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof
EP0737207B1 (en) 1994-01-11 2004-09-22 Dyax Corporation Inhibitors of human plasmin derived from the kunitz domains
US6057287A (en) * 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US5795954A (en) 1994-03-04 1998-08-18 Genentech, Inc. Factor VIIa inhibitors from Kunitz domain proteins
US6008196A (en) * 1994-06-02 1999-12-28 Hoechst Marion Roussel, Inc. Perfluoroalkyl ketone inhibitors of elastase and processes for making the same
US5589359A (en) 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
WO1996004377A1 (en) 1994-08-05 1996-02-15 Chiron Corporation Production of tissue factor pathway inhibitor
US5648331A (en) 1994-08-26 1997-07-15 G.D. Searle & Co. Method of inhibiting tissue ischemia and reperfusion injury
US5914316A (en) 1994-12-16 1999-06-22 Washington University Method of inhibiting intimal hyperplasia
ZA963619B (en) * 1995-05-08 1996-11-22 Scios Inc Protease inhibitor peptides
US5786328A (en) 1995-06-05 1998-07-28 Genentech, Inc. Use of kunitz type plasma kallikrein inhibitors
US5780265A (en) 1995-06-05 1998-07-14 Genentech, Inc. Kunitz type plasma kallikrein inhibitors
US6242414B1 (en) 1995-06-07 2001-06-05 Chiron Corporation Regulation of cytokine synthesis and release
US5736364A (en) 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
JP3469584B2 (ja) 1996-03-11 2003-11-25 バイエル コーポレイション ヒト ビクニン
AU6042298A (en) 1997-01-31 1998-08-25 Human Genome Sciences, Inc. Tissue factor pathway inhibitor-3
US6180607B1 (en) 1999-08-05 2001-01-30 Christopher Davies Protein having proteinase inhibitor activity
US6544760B2 (en) * 1999-12-22 2003-04-08 Zymogenetics, Inc. Kunitz domain polypeptide Zkun11
US20020102703A1 (en) 1999-12-29 2002-08-01 Sheppard Paul O. Kunitz domain polypeptide zkun10
AU2001249074A1 (en) 2000-03-13 2001-09-24 Eli Lilly And Company Human hepatocyte growth factor activator inhibitor homologue
US20040152633A1 (en) 2001-05-31 2004-08-05 Jorgensen Marianne Ulrich Kunitz-type sequences and polypeptides
US20030129659A1 (en) 2001-12-03 2003-07-10 Whelihan E. Fayelle Library screening
NZ534310A (en) * 2002-02-07 2008-03-28 Novozymes Delta Ltd Albumin-fused anti-angiogenesis peptides
US7153829B2 (en) * 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
US6989369B2 (en) 2003-02-07 2006-01-24 Dyax Corp. Kunitz domain peptides
CA2535859A1 (en) 2003-08-14 2005-03-03 Dyax Corp. Endotheliase-2 ligands
US20070020252A1 (en) * 2003-08-29 2007-01-25 Ladner Robert C Modified protease inhibitors
AU2004268145B2 (en) * 2003-08-29 2010-09-16 Takeda Pharmaceutical Company Limited Poly-PEGylated protease inhibitors
US20050164945A1 (en) * 2003-10-21 2005-07-28 Andrew Nixon Endotheliase-1 ligands
US7235530B2 (en) * 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
EP1835926A4 (en) * 2004-11-22 2009-04-01 Dyax Corp PLASMINE-INHIBITING THERAPIES

Also Published As

Publication number Publication date
PL1981519T3 (pl) 2018-07-31
CA2635589A1 (en) 2007-07-12
DK1981519T3 (en) 2018-02-19
JP2009521926A (ja) 2009-06-11
JP5632126B2 (ja) 2014-11-26
LT1981519T (lt) 2018-04-25
HUE038243T2 (hu) 2018-10-29
US20080255025A1 (en) 2008-10-16
EP1981519B1 (en) 2017-12-27
EP1981519A2 (en) 2008-10-22
ES2663497T3 (es) 2018-04-13
WO2007079096A2 (en) 2007-07-12
CA2635589C (en) 2017-01-17
AU2006332774A1 (en) 2007-07-12
WO2007079096A3 (en) 2008-02-14
EP1981519A4 (en) 2010-01-06
JP2012235793A (ja) 2012-12-06
PT1981519T (pt) 2018-02-23
SI1981519T1 (en) 2018-05-31
US8828703B2 (en) 2014-09-09

Similar Documents

Publication Publication Date Title
CY1119967T1 (el) Αναστολη πρωτεασης
CY1114916T1 (el) Μεθοδοι
NO20073368L (no) Amid-promedikament av gemcitabin, sammensetninger og anvendelse derav
EP1704180A4 (en) nucleating
DK2046951T3 (da) Proteasesreeningsmetoder og proteaser identificeret dermed
DE602004024107D1 (de) Vektoren zur gerichteten klonierung
NO20044039L (no) Konjugatorer av terapeutiske eller cytotoksiske midler og biologisk aktive peptider.
CY1106640T1 (el) Αναστολεις κρουζιπαϊνης και αλλων πρωτεασων κυστεϊνης
DK3530673T3 (da) Humaniserede anti-beta7-antagonister og anvendelser deraf
CY1111225T1 (el) Νεα πεπτιδια ως αναστολεις πρωτεασης νs3-σερινης ιου ηπατiτιδας c
CY1109068T1 (el) Υποκατεστημενες πυριδινυλαμινες
EA200701918A1 (ru) Белок липокалин
CY1109741T1 (el) Sns-595 και μεθοδοι χρησης αυτου
ATE424560T1 (de) Marker für neuromyelitis optica
EA200701528A1 (ru) Новые нутрицевтические композиции
PA8508301A1 (es) Inhibidores de la proteina c del procolageno
ATE497506T1 (de) Sars-verwandte proteine
ATE532861T1 (de) Expressionsvektor
ATE543833T1 (de) Bmp-7-varianten-zusammensetzungen, verfahren und verwendungen
TW200700089A (en) Recombinant protein comprising starch binding domain and use thereof
ATE533779T1 (de) Isoliertes photoprotein mtclytin, sowie dessen verwendung
DE50308032D1 (de) Isoliertes fluoreszierendes protein aus clytia gregaria cgfp, sowie dessen verwendung
MX2007011411A (es) Interaccion rage/diaphanous y composiciones relacionadas y metodos.
CY1109904T1 (el) Προαγωγεας της il-18bp, η παρασκευη και χρηση του
ATE505538T1 (de) Dna-vektoren